Method of treating fulminant hepatic failure using DLL4 cytokine
US10328122B2 · kind B2 · utility
0Cited by
0References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 2, 2016 |
| Grant date | Jun 25, 2019 |
| Priority date | — |
| Expiry date | Jan 27, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/0019
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of treating fulminant hepatic failure in a subject, includes administering a therapeutically effective amount of a pharmaceutical composition to the subject, wherein the pharmaceutical composition comprises a DLL4 cytokine. A method of treating liver failure, sub-acute liver failure, chronic liver failure or acute-on-chronic liver failure in a subject, includes administering an therapeutically effective amount of a DLL4 cytokine to the subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.